EC Number   |
Inhibitors |
Structure |
|---|
    2.4.2.14 | 1-alpha-diphosphoryl-2-alpha,3-alpha-dihydroxy-4-beta-cyclopentane-methanol-5-phosphate |
competitive vs. 5-phospho-alpha-D-ribose 1-diphosphate in wild-type and P410W mutant, competition for the amidotransferase C site |
   |
| 2.4.2.14 | 2,4-diamino-6-(3,4,5-trimethoxyanilino)-methylpyrido[3,2-d]pyrimidine |
PY873 |
|
| 2.4.2.14 | 2,4-diamino-6-(3,4,5-trimethoxybenzyl)-5,6,7,8-tetrahydro-quinazoline |
PY899 |
|
| 2.4.2.14 | 2-amino-4-oxo-5-chloropentanoate |
approx. 80% inactivation of NH3-dependent activity after 30 min |
|
| 2.4.2.14 | 5',5'-P1,P4-diguanosine tetraphosphate |
IC50: 0.4 mM, 2 mM, approx. 80% inhibition |
|
| 2.4.2.14 | 5'-p-fluorosulfonylbenzoyladenosine |
inactivation follows pseudo-first order kinetic, AMP, GMP and 5-phospho-alpha-D-ribose 1-diphosphate protect |
|
| 2.4.2.14 | 5-((4-carboxy-4-(4-(((2,4-diaminopyrido[3,2-d]pyrimidine-6-yl)methyl)amino)benzamido)butyl)carbamoyl)isophthalic acid |
- |
|
| 2.4.2.14 | 6-diazo-5-oxo-L-norleucine |
approx. 98% inactivation of amidotransferase activity after 30 min |
|
| 2.4.2.14 | 6-diazo-5-oxo-L-norleucine |
competitive vs. glutamine, inactivation half-life: 11 min |
|
| 2.4.2.14 | 6-diazo-5-oxo-L-norleucine |
- |
|
